Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Single-arm studies for accelerated approval should be used only when the patient population is small or drug activity is high, the Oncology Drugs Advisory Committee says.